Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.

Item

http://www.wikidata.org/entity/Q38093143

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.

@en

type

Item

label

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.

@en

prefLabel

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia.

@en

P1476

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia

@en

P2093

Jordan Baye

http://www.w3.org/2001/XMLSchema#string

Matthew A Cantrell

http://www.w3.org/2001/XMLSchema#string

P2860

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects.

Watchful waiting in benign prostatic hyperplasia.

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.

Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Sildenafil influences lower urinary tract symptoms.

Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

P304

639-649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1243

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Scott Martin Vouri

P577

2013-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236081612

http://www.w3.org/2001/XMLSchema#string

P698

23529917

http://www.w3.org/2001/XMLSchema#string